A randomised, double-blind, placebo-controlled, five parallel group study investigating the efficacy and safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg administered orally once daily) over 12 weeks in drug naive and treated patients with type 2 diabetes with insufficient glycemic control.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2013
At a glance
- Drugs Linagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 17 Sep 2013 A meta-analysis will be presented at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), according to a Boehringer Ingelheim and Eli Lilly media release.
- 18 Nov 2008 Actual patient enrollment was 302, as reported by clinicaltrials.gov.